Here is Why H.C. Wainwright Sees Immense Upside for Viking Therapeutics (VKTX)

Core Viewpoint - Viking Therapeutics (NASDAQ:VKTX) is identified as a promising mid-cap healthcare stock with significant upside potential, projected at nearly 190% from its current price, with a target of $102 per share [1]. Group 1: Analyst Ratings and Price Targets - H.C. Wainwright analyst Joseph Pantginis has reaffirmed a Buy rating on Viking Therapeutics, forecasting a price target of $102 per share [1]. - Consensus estimates indicate a potential upside of over 176% for Viking Therapeutics, with a forecasted target price of $97.27, supported by all 13 analysts assigning Buy ratings [3]. Group 2: Product Development and Market Position - Viking Therapeutics focuses on differentiated VK2735 oral and injectable formulations, which are bolstered by positive outcomes from a Phase 3 study conducted by competitor Eli Lilly, showing oral therapies can effectively maintain weight loss previously associated with injections [2]. - The results from Eli Lilly's study validate Viking's ongoing oral obesity program, reducing commercial risks and increasing investor interest in the company [3]. - Viking Therapeutics specializes in therapies for metabolic and endocrine disorders, particularly targeting obesity, fatty liver, and diabetes through small-molecule drugs [4].